Daily FNArena News - Small Caps

The lead compound of Neuren Pharmaceuticals is being developed to treat brain injuries and with no current competition in the market Bell Potter sees upside from any success.

DJ Carmichael has initiated coverage on Neptune Marine with a Spec Buy rating, viewing the stock as a turnaround story as new management grows a restructured business.

GI Dynamics is developing the EndoBarrier product for use in treating type II diabetes and obesity and Bell Potter sees significant upside potential in the stock.

Following a meeting with management Moelis remains attracted to Thorn Group, seeing value at current levels given the defensive nature of the group’s earnings.

Growth potential as IT junior NEXTDC rolls out a national data centre offering sees Moelis rate the stock as a Buy.

An unusual business model and a solid growth outlook are a positive combination for GR Engineering, reports Macquarie.

Labour hire and replacement group Humanis is delivering earnings growth both organically and via acquisitions and this attractive growth outlook sees Moelis rate the stock as a Buy.

A history of solid earnings growth and rising dividends and expectations of more of the same sees DJ Carmichael initiate coverage on Lycopodium with a Buy rating.

Phosphagenics continues to develop its TPM drug patch delivery technology and Bell Potter sees this as a key advantage for the company in breaking into sizable markets.

REVA Medical has seen the timeline for starting clinical trials of its bioresorbable stent slip but Bell Potter says any associated share price weakness would be a buying opportunity.